Immix Biopharma (IMMX) Times Interest Earned (2021 - 2026)
Immix Biopharma (IMMX) posted Times Interest Earned of -$30.29 for Q1 2026, down 5.02% sequentially from -$28.84 in Q4 2025, and down 182.38% YoY from $36.77 in Q1 2025.
Immix Biopharma (IMMX) Times Interest Earned (2021 - 2026) Analysis & Trends
Immix Biopharma has reported Times Interest Earned for 6 years, with the latest figure at -$30.29 in Q1 2026.
- Quarterly Times Interest Earned fell 182.38% year-over-year to -$30.29 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$101.15 (down 102.86% YoY) and the FY2025 annual result came in at -$1.18, up 17.65% from the prior year.
- Times Interest Earned retreated to -$30.29 in Q1 2026 per IMMX's latest filing, from -$28.84 in the prior quarter.
- Over five years, Times Interest Earned peaked at $417.03 in Q4 2022 and troughed at -$8259.0 in Q2 2022.
- A 5-year average of -$875.41 and a median of -$10.7 in 2024 frame the typical range for Times Interest Earned.
- The widest YoY moves for Times Interest Earned: up 161.68% in 2022, down 182850.63% in 2022.
- Over 5 years, Times Interest Earned stood at $417.03 in 2022, then tumbled by 100.17% to -$0.7 in 2023, then soared by 55.09% to -$0.32 in 2024, then tumbled by 9017.25% to -$28.84 in 2025, then decreased by 5.02% to -$30.29 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$30.29, -$28.84, and -$5.09 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | -9.31 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.31 |
| Mar 31, 2026 | -30.29 |
| Dec 31, 2025 | -28.84 |
| Sep 30, 2025 | -5.09 |
| Jun 30, 2025 | -16.16 |
| Mar 31, 2025 | -10.73 |
| Dec 31, 2024 | -0.32 |
| Sep 30, 2024 | -4.72 |
| Jun 30, 2024 | -2.93 |
| Mar 31, 2024 | -10.70 |
| Dec 31, 2023 | -0.70 |
| Dec 31, 2022 | 417.03 |
| Jun 30, 2022 | -8,259.02 |
| Mar 31, 2022 | -3,427.93 |
| Dec 31, 2021 | -676.09 |
| Sep 30, 2021 | -6.45 |
| Jun 30, 2021 | -4.51 |
| Mar 31, 2021 | -5.90 |